

Treatment Strategy for ecDNA-Driven Tumors Shows Potential

Some tumors are fueled by extrachromosomal DNAs (ecDNAs), free-floating circular chunks of DNA that may make cancers more aggressive.

December 24, 2024 By [National Cancer Institute](#)

By Carmen Phillips

Researchers have identified a way to potentially kill tumors fueled by extrachromosomal DNAs (ecDNAs), free-floating circular chunks of DNA suspected of making cancers more aggressive and helping them thwart all manner of treatments.

With the aid of an [experimental drug](#), scientists have now shown that they can take advantage of an instability in cancer cells created by ecDNAs.

Findings from the study were published November 6 in *Nature*, along with two others on ecDNAs funded by the [Cancer Grand Challenges](#), an international initiative sponsored by NCI and Cancer Research UK.

One of the other studies shows that ecDNAs are found in many more cancers and at much higher levels than previously thought, while the third provides new details about how ecDNAs are passed on in cancer cells as tumors grow. (See below, “More Insights on ecDNAs.”)

“We’ve learned that ecDNAs are a huge problem in cancer,” said Paul Mischel, MD, of Stanford University, the leader of [the Cancer Grand Challenges ecDNA team \(called eDyNAmiC\)](#) and a senior investigator on all three studies.

In the treatment-focused study, Mischel and his colleagues showed that ecDNAs can also cause problems in cancer cells, in the form of serious difficulties copying their DNA in preparation to divide into two new cells. And an experimental drug, called BBI-2779, could exploit those difficulties, they found. In mice with tumors carrying ecDNAs with a cancer-causing genetic [mutation](#), combining BBI-2779 with a drug that targets the mutation [quickly shrank tumors and kept them at bay for relatively long periods](#).

In the study, each drug alone modestly reduced tumor size, Dr. Mischel explained. But, he continued, “when you put the two [drugs] together you get a massive response.”

A closely related drug—called BBI-355—is already [being tested in humans in a small clinical trial](#), both alone and in combination with one of several targeted therapies, depending on the genetic changes that are present in participants' tumors.

What's known about ecDNAs in cancer

Although ecDNAs were first discovered more than 60 years ago, until recently they were a biological mystery. In part, that's because finding them and analyzing their makeup was very difficult.

However, with the aid of numerous advanced technologies, a more complete portrait of ecDNAs is emerging.

For example, it's been well established that only cancer cells have ecDNAs and that they appear to influence cancer cells in important and diverse ways, explained Ian Fingerman, PhD, of NCI's [Division of Cancer Biology](#).

"The more we dig into ecDNAs, the more important they seem to be," Dr. Fingerman said.

He pointed, for example, to research led by Mischel and his Stanford colleague Howard Chang, MD, PhD, which showed that ecDNAs almost always contain cancer-causing genes, known as oncogenes. They also often house many copies of the same [oncogene](#), known as [gene amplification](#), and those genes tend to be very active.

This hyperactivity is partly due to the circular structure of ecDNAs, explained Bishoy Faltas, MD, of Weill Cornell Medicine, who led a separate NCI-funded study of ecDNAs in bladder cancer published in the same issue of Nature. "The circular shape allows the oncogenes on ecDNA to interact more readily with other elements on the ecDNA, leading to increased activity of those genes," Faltas said.

A few years ago, Chang, Mischel and their team made a related and surprising discovery. Much like teenage boys at their first dance, they found, [ecDNAs tend to cluster in large groups, or what they call "hubs."](#) The individual ecDNAs in each hub are physically tethered together, with their close proximity creating a "cooperative environment" in which components on one ecDNA molecule can, and often do, control the activity of components on another.

By hosting amplified oncogenes, Faltas noted, ecDNAs are well suited to helping cancer cells do things like quickly adapt to and fend off treatments. In his team's recent study, for example, they showed that [oncogenes on ecDNAs appeared to be "the keys to \[bladder tumors'\] resistance to chemotherapy,"](#) he explained.

The finding is in-line with others that strongly suggest ecDNAs appear to provide cancer cells and the tumors of which they are apart with some significant advantages. But Mischel and his team wondered whether the oncogene hyperactivity in ecDNAs might also have some disadvantages for

tumors, including something that could be a potentially exploitable weakness.

Taking advantage of conflict

For the study involving BBI-2779, Mischel and his team started with a hunch. Because of the high levels of oncogene amplification in ecDNAs, they suspected that cells with ecDNAs should also have high rates of events called transcription-replication conflicts.

These conflicts are literal physical collisions among molecules in the [nucleus](#) involved in the processes of [transcription](#), during which an [RNA](#) copy of a segment of DNA is made, and [DNA replication](#), which is the copying of DNA in preparation for [cell division](#).

Both transcription and replication are in high gear in cancer cells, so they suspected that there should be plenty of these conflicts, as well as an associated condition called replication stress.

And when replication stress gets severe enough, it can lead to DNA that is so badly damaged it causes cells to die.

They tested their hunch by analyzing cancer cells with ecDNAs that had amplification of a well-known oncogene called MYC and amplification of the same gene on its appropriate [chromosome](#).

They found precisely what they expected to: very high levels of transcription of MYC on ecDNAs compared with its chromosome-bound counterpart, an abundance of evidence of transcription-replication conflicts and replication stress, and plenty of DNA damage.

Exploiting replication stress by blocking CHK1

In the face of such tumultuous conditions, normal cells typically die. But in the case of cancer cells, which are particularly good at skirting death, the researchers suspected that these cells might need an added push.

That push was blocking a protein called CHK1, which acts like a traffic cop in the cell nucleus, slowing or stopping cell division when DNA damage is detected.

That's where BBI-2779 comes in: It blocks CHK1 from performing its duties. In lab experiments, treating ecDNA-containing cancer cells with BBI-2779 caused the equivalent of multiple multi-car pileups, jamming up the transcription and replication machinery and causing mass cell death.

In mice, the drug on its own modestly shrank stomach tumors of ecDNA-containing cancer cells with mutations in an oncogene called FGFR. Treating the mice with infigratinib, which targets cells with FGFR mutations, shrank tumors for a short time, but they quickly regrew as the ecDNA-containing cells ramped up FGFR activity faster than infigratinib could shut it down.

Combining BBI-2779 with infigratinib looked to be the winning recipe, thwarting this adaptation

and keeping tumors from regrowing.

One Trial Underway, Much More Research to Do

The clinical trial of BBI-355 is funded by Boundless Bio, which Mischel and Chang founded. Both now serve on its scientific advisory board.

The trial is the first toe in the water of human studies of ecDNA-directed treatments, Mischel noted. There are likely to be other ways of targeting ecDNA-fueled tumors, he continued.

According to Faltas, there may also be opportunities to prevent ecDNA from forming in the first place. In his group's study, for example, the appearance of ecDNA was linked to the development of mutations caused by an enzyme called APOBEC3. This enzyme can also cause powerful breaks in DNA, he explained, such as those that can fragment it and potentially lead to the formation of structures like ecDNA.

This finding "suggests that APOBEC3-induced mutations either precede or occur at the same time" as ecDNAs are being formed, Faltas said. "So, you start to think, can we intercept the formation of ecDNAs?"

Mischel and his Cancer Grand Challenges colleagues are thinking along the same lines, he explained, with studies already focused on identifying the early events in ecDNA formation and developing methods for monitoring ecDNAs in blood samples.

SIDEBAR

More Insights on ecDNAs

Present in many cancers, sometimes at high levels

In an analysis of tumor samples from nearly 15,000 people, representing nearly 40 types of cancer, [about 17% of tumors had ecDNAs](#), according to findings from a collaborative study from the eDyNAmiC team and the team leading a UK-based project called TracerX. The extent of tumors with ecDNAs varied by cancer type, with some types having ecDNAs in up to 60% of tumors. The study sheds light on the diversity of the "cargo" that ecDNAs carry, Mischel said, including genes that help cancer cells avoid the immune system.

ecDNAs that bind together stay together

A study led by Chang and Mischel showed that individual ecDNAs in cancer cells often carry multiple oncogenes. In addition, they found that, during cell division, [ecDNAs are unequally segregated in the new cells](#), with specific ecDNAs being "co-inherited," leading to successive

generations of cancer cells with ecDNA that closely cooperate.

More common in treated tumors, metastases

In another study from a Cancer Grand Challenges team led by Roel Verhaak, PhD, published October 14 in Nature, researchers found that [ecDNAs were much more common in metastatic tumors](#) and those treated with chemotherapy than in tumors that had yet to be treated. The results, they wrote, suggest that ecDNAs “provide tumors with competitive advantages during cancer progression and metastasis.”

Team science at its finest

The studies illustrate the value of team science initiatives like Cancer Grand Challenges, Fingerman said. “You couldn’t perform work of this scope with one [lead investigator] who has one grant,” he said. “This is a huge effort involving many different researchers from around the world with broad expertise.... The amount of work that goes into producing this sort of research output is incredible.”

[This post](#) was originally published December 5, 2024, by the National Cancer Institute. It is republished with permission.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.cancerhealth.com/blog/treatment-strategy-ecdnadriven-tumors-shows-potential>